Generalised Lipodystrophy research hub

MEASuRE: Metreleptin Effectiveness And Safety Registry

This study, called MEASuRE, is tracking the long-term effects of a medicine called metreleptin for people with rare fat-wasting conditions called lipodystrophy. It's collecting real-world information to better understand how the medicine works and its safety outside of initial trials.

Open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia